Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod versus podophyllotoxin for external anogenital warts
2013-002951-14Phase 3Completed
- Sponsor
- University College London
- Start
- Jan 2019
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in anogenital warts comparing Imiquimod 5% cream with Podophyllotoxin 0.15% cream (2 arms). Primary endpoint: Composite primary outcome: wart clearance and sustained wart-free status. Started Jan 2019; status: completed.
02
Drugs
imiquimodpodofilox
03
Conditions
anogenital warts
Beyond the preview
Go deeper on 2013-002951-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002951-14.